Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer

Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis

(2011) Jin Woo Choi et al.   PLoS Genetics

Activation of NF- B Signaling by Inhibitor of NF- B Kinase   Increases Aggressiveness of Ovarian Cancer

(2010) L. Hernandez et al.   CANCER RESEARCH

p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism

(2010) Prashanth Ak et al.   FASEB JOURNAL

Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis

(2009) J. W. Choi et al.   CARCINOGENESIS

AIMP2 promotes TNF -dependent apoptosis via ubiquitin-mediated degradation of TRAF2

(2009) J. W. Choi et al.   JOURNAL OF CELL SCIENCE

The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans

(2009) Kellie A. Charles et al.   JOURNAL OF CLINICAL INVESTIGATION

Alternative splicing and disease

(2008) Jamal Tazi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Alternative splicing in the NF-κB signaling pathway

(2008) Joshua R. Leeman et al.   GENE

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

(2008) Anwesha Dey et al.   NATURE REVIEWS DRUG DISCOVERY

AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53

(2008) J. M. Han et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA